Device Trial Radar · NCT07484191
Contralateral Claims Study of Clareon Vivity Pro
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
165
Actual
Start
Apr 28, 2026
Primary completion
Oct 28, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test new versions of Clareon Vivity Pro intraocular lenses (IOLs) by comparing them to currently marketed IOLs.
Conditions
- Aphakia
- Presbyopia
Interventions
Clareon Vivity Pro IOLDevice
Investigational UV-absorbing, blue-light filtering (BLF), foldable IOL that provides an extended range of vision from distance to near without increasing the incidence of visual disturbances. IOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.
Clareon Vivity IOLDevice
Currently marketed UV-absorbing, BLF, foldable IOL that provides an extended range of vision from distance to functional near without increasing the incidence of visual disturbances. IOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.
TECNIS PureSee IOLDevice
Currently marketed UV absorbing, violet-light filtering IOL for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia. IOLs are implantable medical devices and are intended for long term use over the lifetime of the pseudophakic subject.
Cataract SurgeryProcedure
Removal of the cloudy lens, followed by implantation of the IOL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean monocular photopic distance-corrected intermediate visual acuity (DCIVA)Time frame: Month 1 postoperative
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
iVision Clinic
Campsie, New South Wales, Australia
Vision Eye Institute - Chatswood
Sydney, New South Wales, Australia
Personaleyes Parramatta
Sydney, New South Wales, Australia
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.